SA521422270B1 - Apol1 مثبطات لـ وطرق لاستخدامها - Google Patents
Apol1 مثبطات لـ وطرق لاستخدامهاInfo
- Publication number
- SA521422270B1 SA521422270B1 SA521422270A SA521422270A SA521422270B1 SA 521422270 B1 SA521422270 B1 SA 521422270B1 SA 521422270 A SA521422270 A SA 521422270A SA 521422270 A SA521422270 A SA 521422270A SA 521422270 B1 SA521422270 B1 SA 521422270B1
- Authority
- SA
- Saudi Arabia
- Prior art keywords
- apol1
- inhibitors
- ways
- ndkd
- fsgs
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862780667P | 2018-12-17 | 2018-12-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SA521422270B1 true SA521422270B1 (ar) | 2024-02-18 |
Family
ID=69182627
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SA521422270A SA521422270B1 (ar) | 2018-12-17 | 2021-06-15 | Apol1 مثبطات لـ وطرق لاستخدامها |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US11618746B2 (https=) |
| EP (1) | EP3897833B1 (https=) |
| JP (1) | JP7573528B2 (https=) |
| KR (2) | KR20260020195A (https=) |
| CN (1) | CN113453760B (https=) |
| AR (1) | AR116913A1 (https=) |
| AU (1) | AU2019405477B2 (https=) |
| CA (1) | CA3121910A1 (https=) |
| CL (1) | CL2021001561A1 (https=) |
| CO (1) | CO2021009053A2 (https=) |
| CR (1) | CR20210383A (https=) |
| DK (1) | DK3897833T3 (https=) |
| DO (1) | DOP2021000116A (https=) |
| EC (1) | ECSP21052184A (https=) |
| FI (1) | FI3897833T3 (https=) |
| IL (2) | IL319575A (https=) |
| JO (3) | JOP20210131A1 (https=) |
| LT (1) | LT3897833T (https=) |
| MA (1) | MA54538A (https=) |
| MX (1) | MX2021007152A (https=) |
| PE (1) | PE20212302A1 (https=) |
| SA (1) | SA521422270B1 (https=) |
| SG (1) | SG11202105769XA (https=) |
| TW (1) | TWI848031B (https=) |
| UA (1) | UA128375C2 (https=) |
| UY (1) | UY38514A (https=) |
| WO (1) | WO2020131807A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11618746B2 (en) | 2018-12-17 | 2023-04-04 | Vertex Pharmaceuticals Incorporated | Inhibitors of APOL1 and methods of using same |
| WO2021154997A1 (en) * | 2020-01-29 | 2021-08-05 | Vertex Pharmaceuticals Incorporated | Inhibitors of apol1 and methods of using same |
| US20210246121A1 (en) * | 2020-02-04 | 2021-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of apol1 inhibitor and methods of using same |
| IL296035A (en) * | 2020-03-06 | 2022-10-01 | Vertex Pharma | Methods of treating apol-1 dependent focal segmental glomerulosclerosis |
| CN115867543A (zh) * | 2020-06-12 | 2023-03-28 | 弗特克斯药品有限公司 | Apol1抑制剂的固体形式及其使用方法 |
| CA3185604A1 (en) * | 2020-06-12 | 2021-12-16 | Vertex Pharmaceuticals Incorporated | Inhibitors of apol1 and use of the same |
| CN115867532A (zh) * | 2020-06-12 | 2023-03-28 | 弗特克斯药品有限公司 | Apol1的抑制剂及其用途 |
| CN116547287B (zh) | 2020-08-26 | 2025-09-26 | 弗特克斯药品有限公司 | Apol1的抑制剂及其使用方法 |
| CN116997546A (zh) * | 2021-02-19 | 2023-11-03 | 梅兹治疗公司 | Apol1抑制剂及使用方法 |
| US20230119114A1 (en) * | 2021-08-26 | 2023-04-20 | Vertex Pharmaceuticals Incorporated | Solid forms of apol1 inhibitors and methods of using same |
| US12612379B2 (en) | 2021-11-30 | 2026-04-28 | Vertex Pharmaceuticals Incorporated | Inhibitors of APOL1 and methods of using same |
| EP4440697A1 (en) * | 2021-11-30 | 2024-10-09 | Vertex Pharmaceuticals Incorporated | Spirocyclic inhibitors of apol1 and methods of using same |
| MX2024008868A (es) * | 2022-01-18 | 2024-09-23 | Maze Therapeutics Inc | Inhibidores de la apolipoproteína l1 (apol1) y métodos de uso. |
| CA3251050A1 (en) * | 2022-02-08 | 2023-08-17 | Vertex Pharmaceuticals Incorporated | 2-METHYL-4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN] DERIVATIVES USED AS APOL1 INHIBITORS AND THEIR METHODS OF USE |
| WO2023194895A1 (en) | 2022-04-06 | 2023-10-12 | Glaxosmithkline Intellectual Property Development Limited | Pyrrol derivatives as inhibitors of apolipoprotein l-1 |
| US20260055083A1 (en) * | 2022-08-19 | 2026-02-26 | Maze Therapeutics, Inc. | Apol1 inhibitors and methods of use |
| EP4735449A1 (en) * | 2023-06-29 | 2026-05-06 | OmniAB, Inc. | Tetracyclic compounds containing a fused indole for treating apol1-mediated chronic kidney disease |
| GB202401326D0 (en) * | 2024-02-01 | 2024-03-20 | Podium Bio Ltd | Novel compounds |
| KR20250122547A (ko) | 2024-02-05 | 2025-08-14 | 서주사이언티픽 주식회사 | AIoT 기반 방사성 동위원소 관리 시스템 |
| WO2026012338A1 (zh) * | 2024-07-09 | 2026-01-15 | 上海旭成医药科技有限公司 | 一种APOLs抑制剂 |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4039676A (en) | 1975-06-23 | 1977-08-02 | Ciba-Geigy Corporation | 2-piperidinoalkyl-1,4-benzodioxans |
| US6518423B1 (en) | 1996-08-09 | 2003-02-11 | Eisai Co., Ltd. | Benzopiperidine derivatives |
| EP0924209B1 (en) | 1997-12-19 | 2003-05-02 | Eli Lilly And Company | Hypoglycemic imidazoline compounds |
| GB9905010D0 (en) | 1999-03-04 | 1999-04-28 | Merck Sharp & Dohme | Therapeutic agents |
| AU7514700A (en) | 1999-09-07 | 2001-04-10 | Syngenta Participations Ag | Cyanopiperidines |
| FR2801585B1 (fr) | 1999-11-25 | 2002-02-15 | Fournier Ind & Sante | Nouveaux antagonistes des recepteurs de l'ii-8 |
| GB0003397D0 (en) | 2000-02-14 | 2000-04-05 | Merck Sharp & Dohme | Therapeutic agents |
| AU2002211828A1 (en) | 2000-10-02 | 2002-04-15 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| FR2824827B1 (fr) | 2001-05-17 | 2004-02-13 | Fournier Lab Sa | Nouveaux derives de 5-phenyl-1h-indole antagoniste des recepteurs de l'interleukine-8 |
| FR2824826B1 (fr) | 2001-05-17 | 2003-11-07 | Fournier Lab Sa | Nouveaux derives de 5-cyano-1h-indole antagonistes des recepteurs de l'interleukine-8 |
| ES2234451T1 (es) | 2001-11-14 | 2005-07-01 | Teva Pharmaceutical Industries Ltd. | Formas cristalinas y amorfas de losartan potasio y procedimiento para su preparacion. |
| WO2003104180A1 (en) * | 2002-06-05 | 2003-12-18 | Natco Pharma Limited | Process for the preparation of 4-(4-fluorobenzoyl) butyric acid |
| WO2004058717A1 (en) | 2002-12-20 | 2004-07-15 | X-Ceptor Therapeutics, Inc. | Isoquinolinone derivatives and their use as therapeutic agents |
| JP2007504221A (ja) | 2003-09-03 | 2007-03-01 | ガラパゴス・エヌブイ | 新規な４−ピペリジンカルボキシアミドおよび５ｈｔ２ａ受容体関連障害に対する薬剤の製造のためのその使用 |
| BRPI0507657A (pt) | 2004-03-03 | 2007-07-10 | Lilly Co Eli | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para tratar um distúrbio, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo |
| AR048523A1 (es) | 2004-04-07 | 2006-05-03 | Kalypsys Inc | Compuestos con estructura de aril sulfonamida y sulfonilo como moduladores de ppar y metodos para tratar trastornos metabolicos |
| WO2007061763A2 (en) | 2005-11-22 | 2007-05-31 | Merck & Co., Inc. | Indole orexin receptor antagonists |
| US8222288B2 (en) | 2006-08-30 | 2012-07-17 | The Regents Of The University Of Michigan | Small molecule inhibitors of MDM2 and the uses thereof |
| JP5406722B2 (ja) | 2006-10-16 | 2014-02-05 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | ブラジキニン１受容体モジュレータとしての置換されたスルホンアミド誘導体 |
| BRPI0721138A2 (pt) | 2006-12-22 | 2014-04-01 | Hoffmann La Roche | Derivados de espiro-piperidina |
| PT2118074E (pt) * | 2007-02-01 | 2014-03-20 | Resverlogix Corp | Compostos para a prevenção e tratamento de doenças cardiovasculares |
| EP2020414A1 (en) | 2007-06-20 | 2009-02-04 | Laboratorios del Dr. Esteve S.A. | spiro[piperidine-4,4'-thieno[3,2-c]pyran] derivatives and related compounds as inhibitors of the sigma receptor for the treatment of psychosis |
| DK2178870T3 (en) | 2007-08-17 | 2018-10-22 | Lg Chemical Ltd | INDOLE AND INDAZOLIC COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSE |
| CN105254557A (zh) | 2009-05-29 | 2016-01-20 | 拉夸里亚创药株式会社 | 作为钙或钠通道阻滞剂的芳基取代羧酰胺衍生物 |
| UA107943C2 (xx) | 2009-11-16 | 2015-03-10 | Lilly Co Eli | Сполуки спіропіперидину як антагоністи рецептора orl-1 |
| AU2010319400B2 (en) | 2009-11-16 | 2013-12-19 | Eli Lilly And Company | Spiropiperidine compounds as ORL-1 receptor antagonists |
| WO2012025155A1 (en) | 2010-08-26 | 2012-03-01 | Novartis Ag | Hydroxamate-based inhibitors of deacetylases |
| BR102012024778A2 (pt) | 2012-09-28 | 2014-08-19 | Cristalia Prod Quimicos Farm | Compostos heteroaromáticos; processo para preparar os compostos, composições farmacêuticas, usos e método de tratamento para as dores aguda e crônica |
| US10130632B2 (en) | 2012-11-27 | 2018-11-20 | Beth Israel Deaconess Medical Center, Inc. | Methods for treating renal disease |
| EP3049405A4 (en) | 2013-09-26 | 2017-03-08 | Pharmakea Inc. | Autotaxin inhibitor compounds |
| EP3461812B1 (en) | 2014-03-27 | 2021-10-13 | Academisch Medisch Centrum | N-(5-(biphen-4-ylmethyloxy)pentyl)-substituted iminosugars as inhibitors of glucosylceramide synthase |
| EP3186225A4 (en) | 2014-08-27 | 2018-02-28 | The Governing Council of the University of Toronto | Cannabinoid type 1 receptor modulators |
| US10654838B2 (en) | 2014-10-08 | 2020-05-19 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Aminopyridine compounds useful as inhibitors of protein prenylation |
| JP2017535545A (ja) | 2014-11-21 | 2017-11-30 | ラボラトリオス・デル・デエレ・エステベ・エセ・ア | 疼痛に対する多様な活性を有するスピロ−イソキノリン−１，４’−ピペリジン化合物 |
| HUE053705T2 (hu) | 2015-08-27 | 2021-07-28 | Pfizer | Biciklusos kondenzált heteroaril- vagy aril- vegyületek IRAK4 modulátorokként |
| WO2017137334A1 (en) | 2016-02-08 | 2017-08-17 | F. Hoffmann-La Roche Ag | Spiroindolinones as ddr1 inhibitors |
| EP3787669A4 (en) | 2018-04-30 | 2022-03-30 | The Trustees of Indiana University | COMPOUNDS FOR MODULATION OF LEVELS OF DDAH AND ADMA AND METHODS OF USE THEM TO TREAT DISEASES |
| IL278785B2 (en) | 2018-05-22 | 2025-03-01 | Ionis Pharmaceuticals Inc | Modulators of apol1 expression |
| US11618746B2 (en) | 2018-12-17 | 2023-04-04 | Vertex Pharmaceuticals Incorporated | Inhibitors of APOL1 and methods of using same |
| US20220144838A1 (en) | 2019-03-13 | 2022-05-12 | Nanjing Immunophage Biotech Co., Ltd. | Compounds as Inhibitors of Macrophage Migration Inhibitory Factor |
| TW202136219A (zh) | 2019-12-19 | 2021-10-01 | 美商卡司馬療法公司 | Trpml調節劑 |
| WO2021154997A1 (en) | 2020-01-29 | 2021-08-05 | Vertex Pharmaceuticals Incorporated | Inhibitors of apol1 and methods of using same |
| US20210246121A1 (en) * | 2020-02-04 | 2021-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of apol1 inhibitor and methods of using same |
| IL296035A (en) | 2020-03-06 | 2022-10-01 | Vertex Pharma | Methods of treating apol-1 dependent focal segmental glomerulosclerosis |
| IL296423A (en) | 2020-04-22 | 2022-11-01 | Anima Biotech Inc | Collagen 1 translation inhibitors and methods of use thereof |
| WO2021220178A1 (en) | 2020-04-29 | 2021-11-04 | Cominnex Zrt. | Iap antagonists and their therapeutic applications |
| JP2023524563A (ja) | 2020-05-07 | 2023-06-12 | ラムバム メド－テック リミテッド | Ａｐｏｌ１－関連疾患の治療に使用するための組成物 |
| CN115867543A (zh) | 2020-06-12 | 2023-03-28 | 弗特克斯药品有限公司 | Apol1抑制剂的固体形式及其使用方法 |
| CA3185604A1 (en) | 2020-06-12 | 2021-12-16 | Vertex Pharmaceuticals Incorporated | Inhibitors of apol1 and use of the same |
| CN115867532A (zh) | 2020-06-12 | 2023-03-28 | 弗特克斯药品有限公司 | Apol1的抑制剂及其用途 |
| CN116547287B (zh) | 2020-08-26 | 2025-09-26 | 弗特克斯药品有限公司 | Apol1的抑制剂及其使用方法 |
| US20230119114A1 (en) | 2021-08-26 | 2023-04-20 | Vertex Pharmaceuticals Incorporated | Solid forms of apol1 inhibitors and methods of using same |
| EP4440697A1 (en) | 2021-11-30 | 2024-10-09 | Vertex Pharmaceuticals Incorporated | Spirocyclic inhibitors of apol1 and methods of using same |
| US12612379B2 (en) | 2021-11-30 | 2026-04-28 | Vertex Pharmaceuticals Incorporated | Inhibitors of APOL1 and methods of using same |
| EP4476228A1 (en) | 2022-02-08 | 2024-12-18 | Vertex Pharmaceuticals Incorporated | 4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran] derivatives as inhibitors of apol1 and methods of using same |
| AU2023219516A1 (en) | 2022-02-08 | 2024-08-22 | Vertex Pharmaceuticals Incorporated | 2-methyl-4-phenylpiperidin-4-ol derivatives as inhibitors of apol1 and methods of using same |
| CN119212986A (zh) | 2022-02-08 | 2024-12-27 | 弗特克斯药品有限公司 | 作为apol1的抑制剂的螺哌啶衍生物及其使用方法 |
| CA3251050A1 (en) | 2022-02-08 | 2023-08-17 | Vertex Pharmaceuticals Incorporated | 2-METHYL-4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN] DERIVATIVES USED AS APOL1 INHIBITORS AND THEIR METHODS OF USE |
-
2019
- 2019-12-17 US US16/717,099 patent/US11618746B2/en active Active
- 2019-12-17 DK DK19839496.7T patent/DK3897833T3/da active
- 2019-12-17 IL IL319575A patent/IL319575A/en unknown
- 2019-12-17 SG SG11202105769XA patent/SG11202105769XA/en unknown
- 2019-12-17 LT LTEPPCT/US2019/066746T patent/LT3897833T/lt unknown
- 2019-12-17 PE PE2021000896A patent/PE20212302A1/es unknown
- 2019-12-17 UY UY0001038514A patent/UY38514A/es active IP Right Grant
- 2019-12-17 CA CA3121910A patent/CA3121910A1/en active Pending
- 2019-12-17 AR ARP190103717A patent/AR116913A1/es unknown
- 2019-12-17 MX MX2021007152A patent/MX2021007152A/es unknown
- 2019-12-17 TW TW108146307A patent/TWI848031B/zh active
- 2019-12-17 KR KR1020267000658A patent/KR20260020195A/ko active Pending
- 2019-12-17 WO PCT/US2019/066746 patent/WO2020131807A1/en not_active Ceased
- 2019-12-17 KR KR1020217022550A patent/KR102912203B1/ko active Active
- 2019-12-17 AU AU2019405477A patent/AU2019405477B2/en active Active
- 2019-12-17 CN CN201980092356.3A patent/CN113453760B/zh active Active
- 2019-12-17 JP JP2021534284A patent/JP7573528B2/ja active Active
- 2019-12-17 EP EP19839496.7A patent/EP3897833B1/en active Active
- 2019-12-17 IL IL283592A patent/IL283592B2/en unknown
- 2019-12-17 MA MA054538A patent/MA54538A/fr unknown
- 2019-12-17 JO JOP/2021/0131A patent/JOP20210131A1/ar unknown
- 2019-12-17 UA UAA202104153A patent/UA128375C2/uk unknown
- 2019-12-17 CR CR20210383A patent/CR20210383A/es unknown
- 2019-12-17 FI FIEP19839496.7T patent/FI3897833T3/fi active
-
2021
- 2021-06-03 JO JOP/2021/0130A patent/JOP20210130A1/ar unknown
- 2021-06-03 JO JOP/2021/0129A patent/JOP20210129A1/ar unknown
- 2021-06-15 SA SA521422270A patent/SA521422270B1/ar unknown
- 2021-06-15 DO DO2021000116A patent/DOP2021000116A/es unknown
- 2021-06-15 CL CL2021001561A patent/CL2021001561A1/es unknown
- 2021-07-09 CO CONC2021/0009053A patent/CO2021009053A2/es unknown
- 2021-07-15 EC ECSENADI202152184A patent/ECSP21052184A/es unknown
-
2023
- 2023-02-07 US US18/106,569 patent/US12060346B2/en active Active
-
2024
- 2024-06-17 US US18/745,762 patent/US20250042878A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA521422270B1 (ar) | Apol1 مثبطات لـ وطرق لاستخدامها | |
| EA202092899A1 (ru) | Гетероарильные соединения для лечения болезни гентингтона | |
| JOP20230272A1 (ar) | مركبات تثبيط rip1 وطرق لتحضير واستخدامها | |
| EA202092896A1 (ru) | Гетероциклические и гетероарильные соединения для лечения болезни гентингтона | |
| EA202092590A1 (ru) | Пиридазиноны в качестве ингибиторов parp7 | |
| EA202092001A1 (ru) | Соединения для лечения болезни гентингтона | |
| EA201990495A1 (ru) | Биарильные соединения, применимые в качестве иммуномодуляторов | |
| EA201990221A1 (ru) | 1,3-дигидроксифенильные производные, применимые в качестве иммуномодуляторов | |
| EA202092086A1 (ru) | Ингибиторы аргиназы | |
| JOP20230035A1 (ar) | مثبطات apol1 وطرق استخدامها | |
| EA201691726A1 (ru) | Новые 6-конденсированные гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b | |
| EA201892229A1 (ru) | Замещенные аминопуриновые соединения, содержащие их композиции и способы лечения с их применением | |
| EA201890338A1 (ru) | Оксадиазольные производные, пригодные в качестве ингибиторов hdac | |
| EA201592126A1 (ru) | 6-мостиковые гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b | |
| MX377916B (es) | Compuestos 4-amino-imidazoquinolina. | |
| EA201790271A1 (ru) | Ингибиторы гликозидазы | |
| EA201691261A1 (ru) | Новые дигидрохинолизиноны для лечения и профилактики инфекции, вызванной вирусом гепатита b | |
| EA201390609A1 (ru) | ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ | |
| EA201790765A1 (ru) | Производные спиродиамина в качестве ингибиторов альдостерон-синтазы | |
| EA201792028A1 (ru) | Альфа-цинамидные соединения и композиции как ингибиторы hdac8 | |
| EA201890592A1 (ru) | Жидкие фармацевтические композиции, содержащие ингибиторы sglt-2 | |
| JO3501B1 (ar) | مشتقات 5-{(بيبرازين - 1-يل)-3-أوكسو - بروبيل}- إيميدازوليدين-2، 4 - دايون كمثبطات ل adamts لمعالجة هشاشة العظام) | |
| EA201692260A1 (ru) | Соединения 1,3,4-тиадиазола и их применение в лечении рака | |
| EA201692470A1 (ru) | Фармацевтические комбинации | |
| EA202091003A1 (ru) | Новые производные пиразолопирролопиримидиндиона в качестве ингибиторов p2x3 |